LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

Kodu・Aktsiate loetelu・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Suletud

SektorTervishoid

20.32 -0.2

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

19.45

Max

20.46

Põhinäitajad
By Trading Economics
Sissetulek	-607K -51M
Müük	-28M 100M
Aktsiakasum	-0.46
Kasumimarginaal	-51.215
Töötajad	1,784
EBITDA	4.1M -44M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+67.42% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-183M 2.2B
Eelmine avamishind	20.52
Eelmine sulgemishind	20.32

Uudiste sentiment

By Acuity

50%

171 / 346 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

28.13 / 31.12 Toetus ja vastupanu

Zai Lab Ltd ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. mai 2026, 22:44 UTC

Omandamised, ülevõtmised, äriostud

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14. mai 2026, 22:27 UTC

Omandamised, ülevõtmised, äriostud

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14. mai 2026, 22:12 UTC

Tulu

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14. mai 2026, 21:52 UTC

Omandamised, ülevõtmised, äriostud

LVMH to Sell Marc Jacobs

15. mai 2026, 00:00 UTC

Tulu

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14. mai 2026, 23:57 UTC

Omandamised, ülevõtmised, äriostud

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14. mai 2026, 23:56 UTC

Omandamised, ülevõtmised, äriostud

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14. mai 2026, 23:56 UTC

Omandamised, ülevõtmised, äriostud

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14. mai 2026, 23:56 UTC

Market Talk

Gold Prices Rise on Strong Demand -- Market Talk

14. mai 2026, 23:56 UTC

Omandamised, ülevõtmised, äriostud

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14. mai 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

14. mai 2026, 23:50 UTC

Market Talk

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14. mai 2026, 23:47 UTC

Tulu

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14. mai 2026, 23:47 UTC

Tulu

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14. mai 2026, 23:46 UTC

Tulu

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14. mai 2026, 23:46 UTC

Tulu

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14. mai 2026, 23:28 UTC

Market Talk

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14. mai 2026, 23:00 UTC

Market Talk

Australia's One Nation Party Leads In The Polls -- Market Talk

14. mai 2026, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

14. mai 2026, 22:46 UTC

Market Talk

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14. mai 2026, 22:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14. mai 2026, 22:35 UTC

Market Talk

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14. mai 2026, 22:11 UTC

Omandamised, ülevõtmised, äriostud

LVMH Agrees to Sell Marc Jacobs -- WSJ

14. mai 2026, 22:06 UTC

Market Talk

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14. mai 2026, 22:04 UTC

Tulu

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14. mai 2026, 22:04 UTC

Tulu

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14. mai 2026, 22:04 UTC

Tulu

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14. mai 2026, 22:00 UTC

Tulu

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14. mai 2026, 21:55 UTC

Tulu

Nu Holdings 1Q EPS 18c >NU

14. mai 2026, 21:55 UTC

Tulu

Nu Holdings 1Q Rev $4.97B >NU

Võrdlus sarnastega

Hinnamuutus

Zai Lab Ltd ADR Prognoos

Hinnasiht

By TipRanks

67.42% tõus

12 kuu keskmine prognoos

Keskmine 34.27 USD 67.42%

Kõrge 44 USD

Madal 21.8 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Zai Lab Ltd ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Zai Lab Ltd ADR aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

28.13 / 31.12Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

171 / 346 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.